Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (Nasdaq: CSTL) is supporting nationwide patient advocacy, community screenings and education throughout May for Skin Cancer Awareness Month. Activities include advocacy walks, symposiums at Fred Hutch, Ohio State (May 9) and Yale (May 12), a May 26 webinar, Sun Bus skin checks (May 15–16) and participation in Nevada’s Biggest Little Skin Check (May 14).
The company partners with AIM at Melanoma, Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus to expand access to early detection and patient education.
Castle Biosciences (NASDAQ:CSTL) announced Mayo Clinic data presented at DDW 2026 showing the TissueCypher test refines risk stratification and informs risk-aligned surveillance for Barrett's esophagus.
In multicenter cohorts, physicians changed surveillance intervals in 55% of patients and aligned recommendations with TissueCypher risk in 79%; TissueCypher classified 84% as low risk versus 38% by a clinical model (κ=0.04).
Castle Biosciences (Nasdaq: CSTL) will present new DecisionDx-Melanoma data at EADO (Apr 23-25, 2026) and ACMS (Apr 30–May 3, 2026).
Multi-center and SEER population analyses show the 31-gene expression profile provides prognostic information beyond AJCC staging, identifying higher-risk patients among thin and early-stage melanoma who may benefit from intensified management.
Castle Biosciences (Nasdaq: CSTL) will release first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026. Management will host a live webcast at 4:30 p.m. ET the same day with a brief Q&A following commentary.
Investors can access the live webcast at the provided events link or via the company's Investor Relations webcast page; a replay will be available after the presentation.
Castle Biosciences (Nasdaq: CSTL) announced it received the 2026 USA TODAY Top Workplaces USA Award on April 10, 2026, marking its fifth consecutive year on the list. The award recognizes organizations with 150+ employees based solely on confidential employee survey feedback.
The program is run by Energage and USA TODAY and measures workplace experience themes tied to high performance; the full 2026 Top Workplaces USA list is available on TopWorkplaces.com.
Castle Biosciences (Nasdaq: CSTL) will present SEER-linked data at AAD 2026 showing that the DecisionDx-Melanoma 31-gene expression profile significantly stratifies five-year melanoma-specific survival within AJCC stages and T categories.
In 1,868 patients (2013–2019), Class 1A versus 2B outcomes differed markedly (T1: 96.7% vs 70.0%; Stage IIB–III: 87.4% vs 48.5%), supporting more personalized, risk-aligned management.
Castle Biosciences (Nasdaq: CSTL) published a prospective multicenter study in Future Oncology showing DecisionDx-Melanoma’s i31-SLNB identifies patients below the NCCN 5% threshold for forgoing SLNB. Key results: 2.6% observed SLN positivity overall for 5% predicted patients; in T1b–T2a; 97.8% three-year RFS in low-risk patients. The i31-SLNB produced TN:FN ratios of 55:1 (T1–T2a) and 73:1 (T1b–T2a), exceeding the 19:1 guideline benchmark. A webcast will be held March 23, 2026, to discuss the data.
Castle Biosciences (Nasdaq: CSTL) reported prospective multicenter results showing DecisionDx-Melanoma’s i31-SLNB accurately predicts sentinel lymph node (SLN) positivity and identifies low-risk patients. In 912 patients across 30 U.S. centers, those with 5% predicted risk had a 2.6% actual SLN positivity rate and 97.8% three-year recurrence-free survival.
Castle Biosciences (Nasdaq: CSTL) will present data at SSO 2026 (March 5–7, 2026) showing DecisionDx-Melanoma’s i31-SLNB algorithm predicts sentinel lymph node (SLN) positivity and may identify T1b–T2a melanoma patients who can safely avoid SLNB. The ePoster (EP49) reports independent validation of an integrated 31‑gene expression profile with clinicopathologic factors to provide personalized SLN risk estimates and support risk‑aligned decision-making.
ePosters will be available in the SSO Exhibit Hall, on the meeting website and in the SSO mobile app; Castle will be at booth #321.
Castle Biosciences (Nasdaq: CSTL) will host a grand opening for its new corporate headquarters in Friendswood, Texas on March 24, 2026 at 3:00 p.m. CT. The purpose-built 23-acre campus features energy-efficient systems, storm-rated design, flexible workspaces and employee amenities.
The facility supports Castle’s clinical testing operations and growth as the company advances its molecular test portfolio; Castle reported $344 million revenue in 2025. The event is by invitation; media may RSVP in advance.